Adverse effects of topical corticosteroids in paediatric eczema: Australasian consensus statement

Emma Mooney, Marius Rademaker, Rebecca Dailey, Ben S Daniel, Catherine Drummond, Gayle Fischer, Rachael Foster, Claire Grills, Anne Halbert, Sarah Hill, Emma King, Elizabeth Leins, Vanessa Morgan, Roderic J Phillips, John Relic, Michelle Anne Rodrigues, Laura Scardamaglia, Saxon Smith, John Su, Orli WargonDavid Orchard

Research output: Contribution to journalReview ArticleResearchpeer-review

Abstract

Atopic eczema is a chronic inflammatory disease affecting about 30 of Australian and New Zealand children. Severe eczema costs over AUD?6000/year per child in direct medical, hospital and treatment costs as well as time off work for caregivers and untold distress for the family unit. In addition, it has a negative impact on a child s sleep, education, development and self-esteem. The treatment of atopic eczema is complex and multifaceted but a core component of therapy is to manage the inflammation with topical corticosteroids (TCS). Despite this, TCS are often underutilised by many parents due to corticosteroid phobia and unfounded concerns about their adverse effects. This has led to extended and unnecessary exacerbations of eczema for children.
Original languageEnglish
Pages (from-to)241-251
Number of pages11
JournalAustralasian Journal of Dermatology
Volume56
DOIs
Publication statusPublished - 2015

Cite this